Revance Therapeutics Inc (STU:RTI)
€ 3.44 -0.08 (-2.25%) Market Cap: 371.12 Mil Enterprise Value: 655.05 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 68/100

Revance Therapeutics Inc at JPMorgan Healthcare Conference Transcript

Jan 16, 2020 / 07:30PM GMT
Release Date Price: €20 (+3.63%)
Federica Lussana;JPMorgan;Investment Banking Associate

Good morning, everyone. My name is Federica Lussana. I'm part of the health care investment banking team of JPMorgan. I'm glad to introduce you to our next presenting company Revance Therapeutics. And our next speaker is going to be Mark Foley, Chief Executive Officer. Just as a kind reminder, there is going to be a breakout session in this room after the presentation. Thank you.

Mark J. Foley
Revance Therapeutics, Inc. - President, CEO & Director

Welcome, everyone. It's my pleasure to give you an overview of the company's 2020 plans and some of the key milestones that we'll be going after this year. Before I get started, I want to put up our forward-looking statement. So Revance is a Silicon Valley biotechnology company that's developed a very innovative, long-acting neuromodulator for use in both aesthetic and therapeutic applications. We're just down the street in Newark, California. And we do both of our drug substance and drug product manufacturing in our facility.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot